Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 9/2019

01-09-2019 | Obesity | Review Article

Metabolically Healthy Obesity and Bariatric Surgery

Authors: Adriana Florinela Cătoi, Luca Busetto

Published in: Obesity Surgery | Issue 9/2019

Login to get access

Abstract

A peculiar category of persons with obesity lacking common metabolic disturbances has been depicted and termed as metabolically healthy obesity (MHO). Yet, although MHO patients are free of obesity-associated complications, they might not be entirely precluded from developing cardio-metabolic disorders. Among patients with morbid obesity (MO) who are referred to bariatric surgery, a subset of metabolically healthy MO (MHMO) has been identified and the question arises if these patients would benefit from surgery in terms of mitigating the peril of cardio-metabolic complications. We revisited the pathophysiological mechanisms that define MHO, the currently available data on the cardio-metabolic risk of these patients and finally we reviewed the benefits of bariatric surgery and the urge to better characterize MHMO before submission to surgery.
Literature
1.
Gonçalves CG, Glade MJ, Meguid MM. Metabolically healthy obese individuals: key protective factors. Nutrition. 2016;32(1):14–20.PubMedCrossRef
2.
3.
Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes. 2011;35:971–81.CrossRef
4.
Blüher M. Are metabolically healthy obese individuals really healthy? Eur Endocrinol. 2014;171(6):R209–19.CrossRef
5.
Stefan N, Häring HU, Hu FB, et al. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1:152–62.PubMedCrossRef
6.
7.
Kramer CK, Zinma B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? Ann Intern Med. 2013;159:758–69.PubMedCrossRef
8.
Stefan N, Häring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. 2018;6(3):249–58.PubMedCrossRef
9.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRef
10.
Heneghan HM, Nissen S, Schauer PR. Gastrointestinal surgery for obesity and diabetes: weight loss and control of hyperglycemia. Curr Atheroscler Rep. 2012;14(6):579–87.PubMedCrossRef
11.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.PubMedCrossRef
12.
National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143–3421.
13.
Grundy SM, Brewer Jr HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004;24(2):e13–8.PubMed
14.
Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059–62.CrossRefPubMed
15.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome :a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRef
16.
Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314:1–16.PubMedCrossRef
17.
Soares MJ, Pannu PK, Calton EK, et al. Vitamin D status and calcium intake in systemic inflammation, insulin resistance and the metabolic syndrome: an update on current evidence. Trends Food Sci Technol. 2017;62:79–90.CrossRef
18.
Brochu M, Tchernof A, Dionne IJ, et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001;86(3):1020–5.PubMed
19.
Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50(12):1499–504.PubMedCrossRef
20.
Karelis A, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 2004;30:569–72.PubMedCrossRef
21.
Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168:1617–24.PubMedCrossRef
22.
Aguilar-Salinas CA, Garcia EG, Robles L, et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab. 2008;93:4075–9.PubMedCrossRef
23.
Meigs JB, Wilson PWF, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91:2906–12.PubMedCrossRef
24.
Plourde G, Karelis AD. Current issues in the identification and treatment of metabolically healthy but obese individuals. Nutr Metab Cardiovasc Dis. 2014;24(5):455–9.PubMedCrossRef
25.
Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118(11):1752–70.PubMedCrossRef
26.
Velho S, Paccaud F, Waeber G, et al. Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr. 2010;64:1043e51.CrossRef
27.
van Vliet Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9.PubMedPubMedCentralCrossRef
28.
Goday A, Benaiges D, Parri A, et al. Can bariatric surgery improve cardiovascular risk factors in the metabolically healthy but morbidly obese patient? Surg Obes Relat Dis. 2014;10:871–6.PubMedCrossRef
29.
Pelascini E, Disse E, Pasquer A, et al. Should we wait for metabolic complications before operating on obese patients? Gastric bypass outcomes in metabolically healthy obese individuals. Surg Obes Relat Dis. 2016;12:49–56.PubMedCrossRef
30.
Lee CJ, Clark JM, Asamoah V, et al. Prevalence and characteristics of individuals without diabetes and hypertension who underwent bariatric surgery: lessons learned about metabolically healthy obese. Surg Obes Relat Dis. 2015;11(1):142–6.PubMedCrossRef
31.
Haskins IN, Chang J, Nor Hanipah Z, et al. Patients with clinically metabolically healthy obesity are not necessarily healthy subclinically: further support for bariatric surgery in patients without metabolic disease? Surg Obes Relat Dis. 2018;14:342–6.PubMedCrossRef
32.
Grundy SM. Over nutrition, ectopic lipid and the metabolic syndrome. Investig Med. 2016;64:1082–6.CrossRef
33.
Grundy SM. Adipose tissue and metabolic syndrome: too much, too little or neither. Eur J Clin Investig. 2015;45(11):1209–17.CrossRef
34.
Blüher S, Schwarz P. Metabolically healthy obesity from childhood to adulthood—does weight status alone matter? Metabolism. 2014;63:1084–92.PubMedCrossRef
35.
Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res. 2017;113:1074–86.PubMedCrossRef
36.
Baglioni S, Cantini G, Poli G, et al. Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell. PLoS One. 2012;7:e36569.PubMedPubMedCentralCrossRef
37.
38.
Blüher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab. 2013;27(2):163–77.PubMedCrossRef
39.
Tan CY, Vidal-Puig A. Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans. 2008;36:935–40.PubMedCrossRef
40.
Smith U, Kahn BB. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med. 2016;280(5):465–75.PubMedPubMedCentralCrossRef
41.
Blüher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol. 2010;21(1):38–43.PubMedCrossRef
42.
Klöting N, Fasshauer M, Dietrich A, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299:E506–15.PubMedCrossRef
43.
O’Connell J, Lynch L, Cawood TJ, et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One. 2010;5:e9997.PubMedPubMedCentralCrossRef
44.
McLaughlin T, Sherman A, Tsao P, et al. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia. 2007;50:1707–15.PubMedCrossRef
45.
Alligier M, Gabert L, Meugnier E, et al. Visceral fat accumulation during lipid overfeeding is related to subcutaneous adipose tissue characteristics in healthy men. J Clin Endocrinol Metab. 2013;98:802–10.PubMedCrossRef
46.
Isakson P, Hammarstedt A, Gustafson B, et al. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes. 2009;58:1550–7.PubMedPubMedCentralCrossRef
47.
Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest. 2017;127:74–82.PubMedPubMedCentralCrossRef
48.
O’Rourke RW. Molecular mechanisms of obesity and diabetes: at the intersection of weight regulation, inflammation, and glucose homeostasis. World J Surg. 2009;33:2007–13.PubMedCrossRef
49.
Badoud F, Perreault M, Zulyniak MA, et al. Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals. FASEB J. 2015;29:748–58.PubMedCrossRef
50.
Hoffstedt J, Arner E, Wahrenberg H, et al. Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity. Diabetologia. 2010;53(12):2496–503.PubMedCrossRef
51.
McLaughlin T, Lamendola C, Coghlan N, et al. Subcutaneous adipose cell size and distribution: relationship to insulin resistance and body fat. Obesity (Silver Spring). 2014;22:673–80.CrossRef
52.
Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609–16.PubMedCrossRef
53.
Macotela Y, Emanuelli B, Mori MA, et al. Intrinsic differences in adipocyte precursor cells from different white fat depots. Diabetes. 2012;61:1691–9.PubMedPubMedCentralCrossRef
54.
Danforth Jr E. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet. 2000;26(1):13.PubMedCrossRef
55.
Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity. Compl Mol Asp Med. 2013;34(1):1–11.CrossRef
56.
Mathew H, Farr OM, Mantzoros CS. Metabolic health and weight: understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism. 2016;65(1):73–80.PubMedCrossRef
57.
Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39–48.PubMedCrossRef
58.
Abraham TM, Pedley A, Massaro JM, et al. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation. 2015;132(17):1639–47.PubMedPubMedCentralCrossRef
59.
60.
Pardina E, Ferrer R, Rossell J, et al. Diabetic and dyslipidaemic morbidly obese exhibit more liver alterations compared with healthy morbidly obese. BBA Clin. 2016;5:54–65.PubMedPubMedCentralCrossRef
61.
Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90(7):4145–50.PubMedCrossRef
62.
Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011;18:629–39.PubMedCrossRef
63.
Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359–404.PubMedCrossRef
64.
Messier V, Karelis AD, Prud’homme D, et al. Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity. 2010;18:911–7.PubMedCrossRef
65.
Martínez-Larrad MT, Corbatón Anchuelo A, Del Prado N, et al. Profile of individuals who are metabolically healthy obese using different definition criteria. A population-based analysis in the Spanish population. PLoS One. 2014;9(9):e106641.PubMedPubMedCentralCrossRef
66.
Alfadda AA, Masood A, Al-Naami MY, et al. A proteomics based approach reveals differential regulation of visceral adipose tissue proteins between metabolically healthy and unhealthy obese patients. Mol Cells. 2017;40(9):685–95.PubMedPubMedCentral
67.
Nazare JA, Smith JD, Borel AL, et al. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the international study of prediction of intra-abdominal adiposity and its relationship with cardiometabolic risk/intra-abdominal adiposity. Am J Clin Nutr. 2012;96:714–26.PubMedCrossRef
68.
Kabir M, Catalano KJ, Ananthnarayan S, et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab. 2005;288(2):E454–61.PubMedCrossRef
69.
Mathieu P, Boulanger MC, Després JP. Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk. Rev Endocr Metab Disord. 2014;15:289–98.PubMedCrossRef
70.
Tinahones FJ, Garrido-Sanchez L, Miranda M, et al. Obesity and insulin resistance-related changes in the expression of lipogenic and lipolytic genes in morbidly obese subjects. Obes Surg. 2010;20:1559–67.PubMedCrossRef
71.
Messier V, Karelis AD, Robillard ME, et al. Metabolically healthy but obese individuals: relationship with hepatic enzymes. Metabolism. 2010;59:20–4.PubMedCrossRef
72.
Ogorodnikova AD, Khan UI, McGinn AP, et al. Ectopic fat and adipokines in metabolically benign overweight/ obese women: the Kronos Early Estrogen Prevention Study. Obesity (Silver Spring). 2013;21:1726–33.CrossRef
73.
Faria G, Gonçalves A, Cunha R, et al. Beyond central adiposity: liver fat and visceral fat area are associated with metabolic syndrome in morbidly obese patients. Int J Surg. 2015 Feb;14:75–9.PubMedCrossRef
74.
Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697–738.CrossRefPubMed
75.
Gesta S, Blüher M, Yamamoto Y, et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci U S A. 2006;103:6676–81.PubMedPubMedCentralCrossRef
76.
Yaghootkar H, Scott RA, White CC, et al. Genetic evidence for a normal-weight “metabolically obese” phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes. 2014;63(12):4369–77.PubMedPubMedCentralCrossRef
77.
Scott RA, Lagou V, Welch RP, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44:991–1005.PubMedPubMedCentralCrossRef
78.
Manning AK, Hivert MF, Scott RA, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet. 2012;44:659–69.PubMedPubMedCentralCrossRef
79.
Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49:17–26.PubMedCrossRef
80.
Trayhurn P, Wang B, Wood IS. Hypoxia and the endocrine and signalling role of white adipose tissue. Arch Physiol Biochem. 2008;114(4):267–76.PubMedCrossRef
81.
Bondia-Pons I, Ryan L, Martinez JA. Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem. 2012;68(4):701–11.PubMedCrossRef
82.
Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. JClin Invest. 2003;112:1796–808.CrossRef
83.
Cancello R, Tordjman J, Poitou C, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes. 2006;55:1554–61.PubMedCrossRef
84.
Harman-Boehm I, Bluher M, Redel H, et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab. 2007;92:2240–7.PubMedCrossRef
85.
Vohl MC, Sladek R, Robitaille J, et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res. 2004;12(8):1217–22.PubMedCrossRef
86.
Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46(11):2347–55.PubMedCrossRef
87.
Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab. 2013;98:E1610–9.PubMedCrossRef
88.
Koster A, Stenholm S, Alley DE, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring). 2010;18:2354–61.CrossRef
89.
Shin MJ, Hyun YJ, Kim OY, et al. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes. 2006;30:1529–34.CrossRef
90.
Wildman RP, Kaplan R, Manson JE, et al. Body size phenotypes and inflammation in the Women’s Health Initiative Observational Study. Obesity (Silver Spring). 2011;19:1482–149.CrossRef
91.
Gómez-Ambrosi J, Catalán V, Rodríguez A, et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care. 2014;37(10):2813–21.PubMedCrossRef
92.
Iglesias Molli AE, Penas Steinhardt A, López AP, et al. Metabolically healthy obese individuals present similar chronic inflammation level but less insulin-resistance than obese individuals with metabolic syndrome. PLoS One. 2017;12(12):e0190528.PubMedPubMedCentralCrossRef
93.
Olefsky JM, Glass CK. Macrophages, inflammation and insulin resistance. Annu Rev Physiol. 2010;72:219–46.CrossRefPubMed
94.
Jiménez A, Perea V, Corcelles R, et al. Metabolic effects of bariatric surgery in insulin-sensitive morbidly obese subjects. Obes Surg. 2013;23(4):494–500.PubMedCrossRef
95.
Soverini V, Moscatiello S, Villanova N, et al. Metabolic syndrome and insulin resistance in subjects with morbid obesity. Obes Surg. 2010;20(3):295–301.PubMedCrossRef
96.
Cătoi AF, Pârvu AE, Andreicuț AD, et al. Metabolically healthy versus unhealthy morbidly obese: chronic inflammation, nitro-oxidative stress, and insulin resistance. Nutrients. 2018;10:1199.CrossRef
97.
Marques-Vidal P, Velho S, Waterworth D, et al. The association between inflammatory biomarkers and metabolically healthy obesity depends of the definition used. Eur J Clin Nutr. 2012;66:426–35.PubMedCrossRef
98.
Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43.PubMedCrossRef
99.
Barbarroja N, López-Pedrera R, Mayas MD, et al. The obese healthy paradox: is inflammation the answer? Biochem J. 2010;430(1):141–9.PubMedCrossRef
100.
van Beek L, Lips MA, Visser A, et al. Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance. Metabolism. 2014;63(4):492–501.PubMedCrossRef
101.
Doumatey AP, Zhou J, Zhou M, et al. Proinflammatory and lipid biomarkers mediate metabolically healthy obesity: a proteomics study. Obesity. 2016;24(6):1257–65.PubMedCrossRef
102.
Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. Eur Heart J. 2015;36:551–9.PubMedCrossRef
103.
Kim TJ, Shin HY, Chang Y, et al. Metabolically healthy obesity and the risk for subclinical atherosclerosis. Atherosclerosis. 2017;262:191–7.PubMedCrossRef
104.
Mongraw-Chaffin M, Foster MC, Kalyani RR, et al. Obesity severity and duration are associated with incident metabolic syndrome: evidence against metabolically healthy obesity from the Multi-Ethnic Study of Atherosclerosis. J Clin Endocrinol Metab. 2016;101:4117–24.PubMedPubMedCentralCrossRef
105.
Appelton. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype. Diabetes Care. 2013;36:2388–94.CrossRef
106.
Soriguer F, Gutierrez-Repiso C, Rubio-Martin E, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab. 2013;98:2318–25.PubMedCrossRef
107.
Hamer M, Bell JA, Sabia S, et al. Stability of metabolically healthy obesity over 8 years: the English Longitudinal Study of Ageing. Eur J Endocrinol. 2015;173:703–8.PubMedCrossRef
108.
Eshtiaghi R, Keihani S, Hosseinpanah F, et al. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran Lipid and Glucose Study. Int J Obes. 2015;39:514–9.CrossRef
109.
Ortega FB, Lee DC, Katzmarzyk PT, et al. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J. 2013;34:389–97.PubMedCrossRef
110.
Garcia-Moll X. Obesity and prognosis: time to forget about metabolically healthy obesity. Eur Heart J. 2018;39(5):407–9.PubMedCrossRef
111.
Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81.PubMedPubMedCentralCrossRef
112.
Lassale C, Tzoulaki I, Moons KGM, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur J Cardiol Eur Heart J. 2018;39(5):397–406.CrossRef
113.
114.
Eckel N, Li Y, Kuxhaus O, et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6(9):714–24.PubMedCrossRef
115.
Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med. 2013;159:758–69.PubMedCrossRef
116.
Caleyachetty R, Thomas N, Toulis KA, et al. Metabolically healthy obese and incident cardiovascular disease events among 3·5 million men and women. J Am Coll Cardiol. 2017;70:1429–37.PubMedCrossRef
117.
Eckel N, Meidtner K, Kalle-Uhlmann T, et al. Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23:956–66.PubMedCrossRef
118.
Mongraw-Chaffin M, Foster MC, Anderson CAM, et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018;71:1857–65.PubMedPubMedCentralCrossRef
119.
Bradshaw PT, Reynolds KR, Wagenknecht LE, et al. Incidence of components of metabolic syndrome in the metabolically healthy obese over 9 years follow-up: the Atherosclerosis Risk In Communities study. Int J Obes. 2018;42:295–301.CrossRef
120.
Jung CH, Lee MJ, Kang YM, et al. The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: the role of systemic inflammation. J Clin Endocrinol Metab. 2015;100(3):934–41.PubMedCrossRef
121.
Achilike I, Hazuda HP, Fowler SP, et al. Predicting the development of the metabolically healthy obese phenotype. Int J Obes. 2015;39(2):228–34.CrossRef
122.
Ricci C, Gaeta M, Rausa E, et al. Long-term effects of bariatric surgery on type II diabetes, hypertension and hyperlipidemia: a meta-analysis and meta-regression study with 5-year follow-up. Obes Surg. 2015;25(3):397–405.CrossRefPubMed
123.
Benaiges D, Flores Le-Roux JA, Pedro-Botet J, et al. Sleeve gastrectomy and Roux-en-Y gastric bypass are equally effective in correcting insulin resistance. Int J Surg. 2013;11:309–13.PubMedCrossRef
124.
Benaiges D, Flores JA, Pedro-Botet J, et al. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery procedure (Roux-en-Y gastric bypass) on lipid profile. Obes Surg. 2012;22:1268–75.CrossRefPubMed
125.
Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.CrossRefPubMed
126.
Sesti G, Folli F, Perego L, et al. Effects of weight loss in metabolically healthy obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet. PLoS One. 2011;6:e17737.PubMedPubMedCentralCrossRef
127.
Moreno-Castellanos N, Guzmán-Ruiz R, Cano DA, et al. The effects of bariatric surgery-induced weight loss on adipose tissue in morbidly obese women depends on the initial metabolic status. Obes Surg. 2016;26(8):1757–67.PubMedCrossRef
128.
Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34.PubMedCrossRef
129.
Ferrer R, Pardina E, Rossell J, et al. Morbidly “healthy” obese are not metabolically healthy but less metabolically imbalanced than those with type 2 diabetes or dyslipidemia. Obes Surg. 2015;25(8):1380–91.PubMedCrossRef
130.
Metadata
Title
Metabolically Healthy Obesity and Bariatric Surgery
Authors
Adriana Florinela Cătoi
Luca Busetto
Publication date
01-09-2019
Publisher
Springer US
Published in
Obesity Surgery / Issue 9/2019
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-019-03964-8

Other articles of this Issue 9/2019

Obesity Surgery 9/2019 Go to the issue

Multimedia Article

What Every Bariatric Surgeon Should Know: How to Relieve Obstruction at the Jejuno-jejunostomy After Roux-en-Y Gastric Bypass

Original Contributions

A 5-Year Follow-up in Children and Adolescents Undergoing One-Anastomosis Gastric Bypass (OAGB) at a European IFSO Excellence Center (EAC-BS)

Review Article

Endoscopic Gastric Plication for Morbid Obesity: a Systematic Review and Meta-analysis of Published Data over Time

Original Contributions

Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model

Original Contributions

Improving Compliance with Very Low Energy Diets (VLEDs) Prior to Bariatric Surgery—a Randomised Controlled Trial of Two Formulations

Original Contributions

Anatomical Relations Between the Esogastric Junction, the Diaphragm, the Pleura, and the Left Lung in Chronic Esogastro-bronchial and/or Esogastro-pleural Fistulas After Sleeve Gastrectomy